The GuidAge study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761® for prevention of Alzheimer disease in patients over 70 with a memory complaint

Neurology

Volumn 67, Issue 9 SUPPL. 3, 2006, Pages

  Vellas, B ^a,b,c   Andrieu, S ^a,b,d   Ousset, P J ^a,b,c   Ouzid, M ^e   Mathiex Fortunet, H ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Toulouse University   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; DRUG EFFECT; EUROPE; FOLLOW UP; HUMAN; INCIDENCE; MEDICAL PRACTICE; MEMORY DISORDER; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33750576826     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.67.9_suppl_3.s6     Document Type: Article

References (29)

1. NCCAM. Ginkgo biloba Prevention Trial in Older Individuals. Release Date: February 26, 1999. RFA: AT-99-001. P.T. National Center for Complementary and Alternative Medicine (NCCAM). National Institute on Aging (NIH). Letter of Intent Receipt Date: April 21, 1999. Application Receipt Date: May 21, 1999.
2. in't Veld BA, Launer LJ, Breteler MM, Hofman A, Stricker BH. Pharmacologic agents associated with a preventive effect on Alzheimer disease: a review of the epidemiologic evidence. Epidemiol Rev 2002;24:248-268.
3. Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and antioxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761®). J Mol Cell Cardiol 1997;29:733-742.
4. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb 761®. Proc Natl Acad Sci USA 2002;99:12197-12202.
5. Bastianetto S, Quirion R. EGb 761® is a neuroprotective agent against beta-amyloid toxicity. Cell Mol Biol 2002;48:693-697.
6. Leininger-Muller B, Jolivalt C, Bertrand P, Siest G. Oxidation of human apolipoprotein E: isoform susceptibility and protection with Ginkgo biloba extract (EGb 761®). Advances in Ginkgo biloba Extract Research, Ginkgo biloba Extract (EGb 761®): In Parker L, Christen Y, eds. Lessons from cell biology. Vol 7. Paris: Elsevier, 1998;57-68.
7. Christen Y. From clinical observations to molecular biology: Ginkgo biloba extract EGb 761®, a success for reverse pharmacology. Curr Top Nutraceutical Res 2003;1:59-72.
8. Christen Y. Ginkgo biloba and neurodegenerative disorders. Front Biosci 2004;9:3091-3104.
9. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55:1409-1415.
10. Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761® in dementia. Dement Geriatr Cogn Disord 2000;11:230-237.
11. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183-1194.
12. Kanowski S, Hermann WM, Stephan K, Wierich W, Hörr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761® in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
13. Hofferberth B. The efficacy of EGb 761® in patients with senile dementia of the Alzheimer type. A double-blind, placebo controlled study on different levels of investigation. Hum Psychopharmacol 1994;9:215-222.
14. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North American EGb Study Group. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-1332.
15. Le Bars PL. Response patterns of EGb 761® in Alzheimer disease: influence of neuropsychological profiles. Pharmacopsychiatry 2003;36(suppl 1):S50-55.
16. Andrieu S, Gillette S, Amouyal K, et al., for the EPIDOS Study. Association of Alzheimer disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS Study. J Gerontol [A] Biol Sci Med Sci 2003;58:372-377.
17. Dartigues JF, Fabrigoule C, Letenneur L, Amieva H, Thiessard F, Orgogozo JM. Epidemiology of memory disorders. Therapie 1997;52:503-506.
18. Dufouil C, Fuhrer R, Alperovitch A. Subjective cognitive complaints and cognitive decline: consequence or predictor? The epidemiology of vascular aging study. J Am Geriatr Soc 2005;53:616-621.
19. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer disease: the Baltimore Longitudinal Study of Aging. Neurology 2000;54:2072-2077.
20. Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer disease. Stat Med 2000;19:1481-1493.
21. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002;59:1764-1767.
22. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761® in dementia of the Alzheimer type. J Psychiatr Res 1997;31:645-655.
23. Delcourt C, Cristol JP, Tessier F, Léger CL, Descomps B, Papoz L, and the POLA Study Group. Age-related macular degeneration and antioxidant status in the POLA Study. Arch Ophthalmol 1999;117:1384-1390.
24. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology 1988;8:900-903.
25. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
26. Berg L. Clinical dementia rating scale. Br J Psychiatr 1984;145:339.
27. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
28. Cardebat D. Evocation lexicale formelle et sémantique chez des subjects normaux. Performances et dynamique de production en fonction de l'âge, du sexe et du niveau d'étude. Acta Neurol Belg 1990;90:207-217.
29. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Motor Skills 1958;8:271-276.